Last updated: October 30, 2026
Lotrel is the fixed-dose combination of amlodipine besylate and benazepril hydrochloride, approved by the U.S. Food and Drug Administration in 1995 for hypertension. Its commercial value came from combining two established antihypertensive mechanisms in a once-daily capsule. The product no longer has meaningful branded exclusivity in the United States. Generic amlodipine/benazepril products dominate the market, while the Novartis brand has limited commercial relevance.
Lotrel’s financial trajectory followed a familiar mature-product pattern: strong demand during the branded period, rapid erosion after generic entry, and eventual transition to a low-price, high-volume combination market. The product remains clinically relevant, but its value is concentrated in generic manufacturing scale, pharmacy access, and formulary positioning rather than patent protection.
What is Lotrel and how does the product work?
Lotrel combines:
| Component |
Drug class |
Primary role |
| Amlodipine besylate |
Dihydropyridine calcium-channel blocker |
Produces arterial vasodilation |
| Benazepril hydrochloride |
Angiotensin-converting enzyme inhibitor |
Reduces angiotensin II formation and aldosterone activity |
The approved strengths include combinations ranging from 2.5 mg/10 mg to 10 mg/40 mg of amlodipine and benazepril, depending on the marketed dosage presentation. Lotrel is administered once daily and is intended for patients whose blood pressure is not adequately controlled with monotherapy or who require combination treatment.
The product’s clinical value is based on complementary pharmacology. Amlodipine lowers peripheral vascular resistance, while benazepril suppresses the renin-angiotensin system. The combination can improve blood-pressure control without requiring separate prescriptions for the two ingredients.
The label also contains class-related safety considerations, including fetal toxicity associated with ACE inhibitors, angioedema, hyperkalemia, renal-function changes, and peripheral edema associated with amlodipine. These risks affect prescribing but do not create a current commercial barrier because physicians have broad experience with both ingredients. (U.S. Food and Drug Administration [FDA], 2019)
When did Lotrel receive FDA approval?
The FDA approved Lotrel in 1995. The reference product was developed and commercialized by Novartis, following the company’s historical cardiovascular franchise strategy around ACE inhibitors, calcium-channel blockers, and fixed-dose combinations.
| Milestone |
Timing |
| FDA approval of Lotrel |
1995 |
| Branded expansion across multiple strengths |
Late 1990s and early 2000s |
| Key composition patent expiration period |
Mid-2010s |
| Generic competition |
Established by the late 2000s and early 2010s |
| Current market structure |
Primarily generic |
The product entered a market in which hypertension treatment was moving toward combination therapy. However, the active ingredients were individually well established. That reduced the long-term commercial protection available from the combination itself.
What patents protected Lotrel?
Lotrel’s principal historical patent protection centered on the combination of amlodipine and benazepril rather than on new molecular entities. Public patent records identify U.S. Patent No. 5,591,762 as a key historical patent associated with the combination. The patent was assigned to or associated with Novartis-related entities and had an expiration date in the mid-2010s, subject to applicable patent-term adjustments or extensions.
| Patent category |
Historical protection |
Current commercial effect |
| Amlodipine composition patents |
Protected the active ingredient historically |
Expired |
| Benazepril composition patents |
Protected the active ingredient historically |
Expired |
| Amlodipine/benazepril combination patent |
Covered the fixed-dose combination |
Expired |
| Formulation and dosage-strength claims |
Supported selected presentations |
No meaningful current exclusivity |
| Method-of-use claims |
Related to treatment of hypertension |
Limited practical blocking power after generic entry |
The Orange Book historically listed patents associated with Lotrel, but those listings no longer provide a material barrier to generic competition. Current patent status should be assessed through the FDA Orange Book and USPTO records for the specific reference-listed drug and dosage form. The commercial conclusion is clear: Lotrel is not protected by a currently valuable U.S. compound or combination patent estate. (FDA, 2024a; United States Patent and Trademark Office [USPTO], n.d.)
When did Lotrel lose exclusivity?
Lotrel lost effective market exclusivity when abbreviated new drug application sponsors began receiving approval for generic amlodipine/benazepril products. The relevant loss occurred well before the expiration of every possible secondary patent issue because the product’s market was already exposed to generic substitution and price competition.
The practical exclusivity timeline was:
- 1995: FDA approval of the branded combination.
- Late 1990s through mid-2000s: branded growth supported by physician familiarity and fixed-dose convenience.
- Late 2000s: generic applications and commercial entry began to change the market.
- Mid-2010s: expiration of key combination protection removed remaining patent-based defenses.
- Subsequent years: broad generic supply and low reimbursement rates reduced branded value.
Lotrel did not have the commercial profile of a biologic or a high-cost specialty drug. Once generic versions became substitutable, payers and pharmacy benefit managers had strong incentives to move utilization away from the brand.
What is the Orange Book status of Lotrel?
Lotrel is an FDA-approved reference product, but its Orange Book position does not create meaningful current exclusivity. The key issue is no longer whether the product has been approved, but whether any unexpired listed patent can delay or block an ANDA applicant.
For a mature combination product such as Lotrel, the relevant regulatory structure is:
| Regulatory issue |
Lotrel position |
| Reference-listed drug |
Yes |
| NDA pathway |
Original branded NDA |
| ANDA competition |
Established |
| Paragraph IV significance |
Primarily historical |
| Current regulatory exclusivity |
None of material commercial importance |
| Generic substitution |
Widely available, subject to state substitution rules |
Paragraph IV challenges likely mattered during the period when the key combination patent remained listed. Today, a Paragraph IV strategy against Lotrel would not normally be the central commercial issue because the core market is already genericized. The competitive question is manufacturing cost, supply reliability, dosage coverage, and contracting.
Which companies challenge or compete with Lotrel?
The current competitive landscape includes generic manufacturers of amlodipine/benazepril and manufacturers of alternative fixed-dose antihypertensive combinations.
Generic competition has historically included large U.S. and international suppliers such as Teva, Sandoz, Mylan, Dr. Reddy’s Laboratories, Lupin, and other ANDA holders, depending on the specific strength and marketing status. Product availability varies by dosage strength, National Drug Code, manufacturer, and supply conditions.
The broader therapeutic competitors include:
- Amlodipine monotherapy
- Benazepril monotherapy
- Amlodipine/benazepril generics
- Amlodipine/valsartan
- Amlodipine/olmesartan
- Lisinopril/amlodipine
- ACE inhibitor/thiazide combinations
- Angiotensin receptor blocker/thiazide combinations
The principal commercial substitute is often not another branded combination. It is separate generic prescriptions for amlodipine and an ACE inhibitor. Physicians may prescribe the components separately when titration flexibility, formulary pricing, or tablet availability is more favorable.
How strong is the Lotrel patent estate?
Lotrel has a weak current patent estate and a stronger historical estate.
Historical strength
The fixed-dose combination provided a defensible product distinction during the branded period. A combination patent could delay direct generic versions if the patent claims were valid, enforceable, and listed in the Orange Book. The multiple dosage strengths also created practical product-line protection.
Current strength
The estate is commercially weak because:
- The active ingredients are long off-patent.
- The principal combination patent protection expired.
- Generic manufacturers have established regulatory pathways.
- Physicians can prescribe the two ingredients separately.
- Payers have little reason to reimburse a premium for the brand.
- Formulation differences are unlikely to support a durable market monopoly.
Formulation patents have limited value where the generic product can use a non-infringing formulation while delivering the same active ingredients and strength. Method-of-use patents also have reduced impact where the approved indication is broad hypertension treatment and generic labeling can rely on the reference product’s labeling through the FDA’s regulatory framework.
What generic entry risks exist for Lotrel?
Generic entry risk is effectively realized rather than prospective. The major commercial risks are now generic price erosion, supply fragmentation, and substitution away from the brand.
| Risk |
Impact on Lotrel |
| ANDA competition |
Eliminates branded pricing power |
| Pharmacy substitution |
Reduces brand prescription volume |
| Payer exclusion |
Limits reimbursement |
| Separate-component prescribing |
Weakens fixed-dose differentiation |
| Dosage-strength competition |
Splits demand across suppliers |
| Manufacturing disruptions |
Creates temporary shortages but not durable brand recovery |
Generic pricing can fall sharply after several suppliers enter. The magnitude depends on the number of approved manufacturers, contracting arrangements, wholesaler inventory, and the presence of restricted or discontinued suppliers. Because amlodipine and benazepril are established small molecules, manufacturing know-how is widely distributed.
What is Lotrel’s financial trajectory?
Novartis has not generally reported Lotrel as a standalone revenue line in its public annual reports. That prevents a precise product-level revenue series from being constructed from company filings alone. The product’s financial trajectory can nevertheless be characterized from its market structure and public reporting.
| Period |
Financial profile |
| 1995 to early 2000s |
Branded growth from hypertension prevalence and combination convenience |
| Mid-2000s |
Mature-brand revenue with increasing generic and therapeutic competition |
| Late 2000s to mid-2010s |
Rapid erosion from generic entry and patent expiry |
| After mid-2010s |
Limited branded revenue; generic market value shifts to manufacturers |
| Current period |
Low-price, mature generic category with volume-driven economics |
Lotrel’s peak revenue was likely far below the scale of Novartis’s major cardiovascular blockbusters, such as Diovan and certain other large primary-care products. The product was commercially important as part of a broader hypertension portfolio, but it was not a durable growth asset after generic competition became established.
The financial effects of loss of exclusivity included:
- Lower net price per capsule
- Reduced branded prescription volume
- Higher rebate pressure
- Greater dependence on formulary access
- Loss of promotional return on investment
- Reduced value of the brand’s sales infrastructure
For generic manufacturers, the economics are different. Revenue per unit is low, but demand is persistent because hypertension is a chronic condition. Profitability depends on scale, procurement, manufacturing utilization, product availability, and the ability to maintain approval across multiple strengths.
How does Lotrel compare with competing antihypertensive products?
| Product category |
Patent position |
Commercial advantage |
Key limitation |
| Generic Lotrel |
Off-patent |
One-pill combination |
Low pricing and many suppliers |
| Amlodipine alone |
Off-patent |
Low cost and broad familiarity |
May require a second drug |
| Benazepril alone |
Off-patent |
Established ACE inhibitor |
Less convenient when combination therapy is needed |
| Amlodipine/valsartan |
Off-patent in major markets |
ARB option for selected patients |
Often higher cost than older combinations |
| Amlodipine/olmesartan |
Off-patent |
Strong fixed-dose positioning |
Similar generic pricing pressure |
| Branded newer combinations |
Variable |
Differentiated delivery or marketing |
Limited payer willingness to pay |
Lotrel’s strongest competitive attribute is simplicity. Its weakest attribute is the absence of a proprietary feature that justifies a premium over separate generic ingredients.
What manufacturing and intellectual-property barriers remain?
The manufacturing barrier is modest. Amlodipine and benazepril are chemically established active pharmaceutical ingredients with mature supply chains. Manufacturers must still demonstrate bioequivalence, control impurity profiles, validate manufacturing processes, and comply with current good manufacturing practice requirements.
The primary barriers are operational:
- FDA inspection readiness
- Reliable active-ingredient sourcing
- Stability across the approved shelf life
- Consistent dissolution and content uniformity
- Packaging and labeling compliance
- Supply continuity across multiple dosage strengths
These barriers can affect individual suppliers, but they do not protect the Lotrel brand from market competition. No biologic comparability issue applies. Lotrel is a conventional small-molecule combination, so biosimilar risk is not relevant. The relevant pathway is ANDA approval, not 351(k) biosimilar approval.
What litigation and settlement issues affect Lotrel?
Lotrel’s central litigation risk was historically linked to generic challenges against listed patents. Once the principal combination patents expired and multiple ANDAs were approved, litigation ceased to be a meaningful driver of the product’s economics.
There is no current litigation framework comparable to the active patent disputes surrounding high-value specialty drugs or biologics. Settlement agreements, if entered during the earlier Paragraph IV period, would have affected generic launch timing. Their present commercial effect is limited because the market has already transitioned to generic supply.
What is the outlook for the Lotrel market?
The Lotrel market should remain stable in clinical demand and unattractive in branded investment value. Hypertension creates a large recurring patient base, but the product’s low unit price and generic competition limit revenue growth.
The likely market characteristics are:
- Stable or modestly growing prescription demand
- Continued generic substitution
- Low branded pricing power
- Periodic supply volatility by manufacturer
- Competition from separate-component prescribing
- Limited opportunity for patent-based lifecycle management
A meaningful commercial opportunity would require a new formulation, adherence technology, or delivery system with separate patent protection and demonstrable clinical or economic value. The existing Lotrel product does not have that protection.
Key Takeaways
- Lotrel is the amlodipine/benazepril fixed-dose combination approved by the FDA in 1995.
- The product’s key value proposition is once-daily combination therapy for hypertension.
- Its principal historical combination patent protection expired in the mid-2010s.
- Generic competition is established, and current branded exclusivity is not commercially meaningful.
- Novartis does not generally disclose Lotrel revenue as a standalone line item.
- The brand’s financial trajectory shifted from mature branded revenue to post-exclusivity erosion and low-value residual sales.
- Generic manufacturers compete primarily on price, supply reliability, dosage-strength coverage, and contracting.
- No biosimilar pathway applies because Lotrel is a conventional small-molecule product.
- Current patent, formulation, and method-of-use barriers are insufficient to support premium branded pricing.
- The market remains clinically durable but financially mature and genericized.
FAQs
Is Lotrel still sold as a brand-name drug?
Brand availability depends on market and channel, but generic amlodipine/benazepril products dominate U.S. prescribing. The branded product has limited commercial importance compared with its pre-generic period.
Can a patient take amlodipine and benazepril separately instead of Lotrel?
Yes. Separate prescriptions can provide the same active ingredients, although the fixed-dose product may reduce pill burden and simplify administration.
Does Lotrel have any remaining U.S. patent protection?
The key historical combination protection has expired. Any current patent question must be evaluated against the FDA Orange Book and USPTO records for the relevant dosage form, but there is no known commercially meaningful exclusivity barrier.
Is Lotrel subject to biosimilar competition?
No. Biosimilars apply to biological products. Lotrel is a small-molecule combination and is subject to generic ANDA competition.
Why can generic Lotrel remain commercially viable despite low prices?
Hypertension is chronic and widespread, creating recurring demand. Generic manufacturers can earn returns through high volume, low-cost production, broad pharmacy distribution, and efficient procurement.
References
-
Novartis AG. (Various years). Annual report. Basel, Switzerland: Novartis AG.
-
U.S. Food and Drug Administration. (2019). Lotrel (amlodipine besylate and benazepril hydrochloride) prescribing information. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. Silver Spring, MD: FDA.
-
United States Patent and Trademark Office. (n.d.). Patent Center and patent search records. Alexandria, VA: USPTO.
-
U.S. Food and Drug Administration. (2018). Generic drugs: Questions and answers. Silver Spring, MD: FDA.
